deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 8-arm NCT05917470

A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.

A Phase 1/2 Study of ONCT-534 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Sponsor: Oncternal Therapeutics, Inc

Conditions Metastatic Castration-resistant Prostate Cancer
Interventions ONCT-534
Updated 14 times since 2023 Last updated: Dec 9, 2024 Started: Sep 20, 2023 Primary completion: Sep 12, 2024 Completion: Sep 12, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Oncternal Therapeutics, Inc. announced on 12 SEP 2024 its decision to discontinue its clinical trials evaluating ONCT-534, its dual action androgen receptor inhibitor for the treatment of patients with metastatic castration resistant cancer.

Other terminated trials from Oncternal Therapeutics, Inc

More terminations from Oncternal Therapeutics, Inc

Other Metastatic Castration-resistant Prostate Cancer trials with similar outcome

Browse all Metastatic Castration-resistant Prostate Cancer trials

This PHASE1/PHASE2 trial investigates Metastatic Castration-resistant Prostate Cancer and is currently terminated or withdrawn. Oncternal Therapeutics, Inc leads this study, which shows 14 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Feb 2024 · 3 months · monthly snapshotRecruiting~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jan 2025 · 3 months · monthly snapshotTerminated~Jan 2025 – present · 18 months · monthly snapshotTerminated

Change History

14 versions recorded

  1. Jan 2025 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Oct 2024 — Jan 2025 [monthly]

    Terminated PHASE1/PHASE2

    Status: Recruiting → Terminated

  3. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE1/PHASE2

  4. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

  5. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 9 earlier versions

  1. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  2. Apr 2024 — May 2024 [monthly]

    Recruiting PHASE1_PHASE2

  3. Mar 2024 — Apr 2024 [monthly]

    Recruiting PHASE1_PHASE2

  4. Feb 2024 — Mar 2024 [monthly]

    Recruiting PHASE1_PHASE2

  5. Nov 2023 — Feb 2024 [monthly]

    Recruiting PHASE1_PHASE2

  6. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Sep 2023 — Oct 2023 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  8. Aug 2023 — Sep 2023 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  9. Jul 2023 — Aug 2023 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Oncternal Therapeutics, Inc
Data source: Oncternal Therapeutics, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations